The company is a supplier of krill-derived products with a fully owned supply chain, with operations spanning from harvesting krill in Antarctica with owned vessels including distribution from Uruguay, and processing of krill into oil products in the United States. Category-defining product launches and deep R&D investment position the company for premium pricing and margin expansion, with sustainability leadership supporting market share gains in global health and nutrition markets.
Cyborg Score Rationale
The stock has shown a 47.31% increase over the past year, reflecting market confidence in its positioning. However, stricter environmental regulations and heavy reliance on krill products expose the company to supply and demand risks, with high capital requirements pressuring profitability. The company operates in growing omega-3 and nutraceutical markets but faces execution risks.
Top Insights
The company generates the majority of its revenue from the Human Health Ingredients segment, which includes Superba, Lysoveta, PL+ Algae, and the company's Houston manufacturing plant
The company operates through three segments: Human Health Ingredients (HHI), Consumer Health Products, and Emerging Business, with emerging businesses including therapeutic candidates for cardiometabolic diseases and circular economy products
Expanding omega-3 market share, new products, and major retail partnerships could significantly boost revenue, with centralizing resources expected to improve efficiency and preserve margins
Aker BioMarine ASA is a subsidiary of Aker ASA, providing strategic backing from a diversified industrial conglomerate
Named Competitors
Omega-3 and Fish Oil Supplements — Traditional competing omega-3 source
Krill-Derived Ingredients — Direct krill products competitor
Recent Developments
(January 2026) Stock trading at 98.70 NOK with 47% YoY appreciation and analyst target of 72.74 NOK average